NLRP3 and cancer: Preclinical studies indicate that treatment with anti-PD-1 antibodies leads to the activation of the PD-L1-NLRP3 inflammasome signaling pathway in cancer cells, resulting in increased recruitment of PMN-MDSCs to the TME, thereby acting as a mechanism of acquired resistance.